secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2022-04-28T23:59:59+00:00
Accession:  0001628280-22-011120
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion appoints Stephen Rocamboli to board; Dr. Mark McGovern resigns
-----------------------------------------------------------------------

- Mark McGovern resigned from board effective April 28, 2022; no disagreement cited.
- Stephen Rocamboli elected to fill vacancy; will serve on Audit Committee.
- Rocamboli is CEO of Perla Therapeutics, with prior life science board and executive roles.
- Esperion expects topline readout of CLEAR Outcomes trial in Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828022011120/0001628280-22-011120-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828022011120/espr-20220428.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-011120

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer